← Back to All US Stocks

BNR Stock Analysis - Burning Rock Biotech Ltd AI Rating

BNR Nasdaq Services-Medical Laboratories CIK: 0001792267
Recently Updated • Analysis: Mar 21, 2026 • SEC Data: 2026-03-21
AI Rating
HOLD
5% Confidence

📊 BNR Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: N/A
Current Ratio: N/A
Debt/Equity: N/A
EPS: $0.00
AI Rating: HOLD with 5% confidence

Investment Thesis

Insufficient financial data available for fundamental analysis. SEC EDGAR filings contain no measurable income statement, balance sheet, or cash flow metrics. Cannot assess profitability, financial health, or growth quality without core financial statements.

BNR Strengths

  • + Company is publicly listed on Nasdaq with SEC reporting obligations
  • + Operates in medical laboratory services sector with potential market relevance
  • + SEC registration indicates regulatory oversight and disclosure requirements

BNR Risks

  • ! Complete absence of reported revenue, income, and asset data
  • ! No financial metrics available to evaluate operational performance or solvency
  • ! Potential non-reporting status or incomplete SEC filings preventing fundamental analysis
  • ! Zero insider trading activity in past 90 days suggests limited stakeholder confidence signals
  • ! Unable to assess cash burn rate, debt obligations, or liquidity position

Key Metrics to Watch

BNR Financial Metrics

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

BNR Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

BNR vs Healthcare Sector

How Burning Rock Biotech Ltd compares to Healthcare sector averages

Net Margin
BNR 0.0%
vs
Sector Avg 12.0%
BNR Sector
ROE
BNR 0.0%
vs
Sector Avg 15.0%
BNR Sector
Current Ratio
BNR 0.0x
vs
Sector Avg 2.0x
BNR Sector
Debt/Equity
BNR 0.0x
vs
Sector Avg 0.6x
BNR Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

BNR Balance Sheet & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

BNR Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

BNR SEC Filings

Access official SEC EDGAR filings for Burning Rock Biotech Ltd (CIK: 0001792267)

📋 Recent SEC Filings

Date Form Document Action
Feb 13, 2024 SC 13G ea193271-13glavbio5_burning.htm View →
Jan 10, 2024 SC 13G bnr_11024.htm View →
Feb 10, 2023 SC 13G bnr_21023.htm View →
Aug 6, 2021 SC 13G d199730dsc13g.htm View →
Aug 4, 2021 SC 13G BurningRockBiotech30072021.txt View →

Frequently Asked Questions about BNR

What is the AI rating for BNR?

Burning Rock Biotech Ltd (BNR) has an AI rating of HOLD with 5% confidence, based on fundamental analysis of SEC EDGAR filings.

What are BNR's key strengths?

Company is publicly listed on Nasdaq with SEC reporting obligations. Operates in medical laboratory services sector with potential market relevance.

What are the risks of investing in BNR?

Complete absence of reported revenue, income, and asset data. No financial metrics available to evaluate operational performance or solvency.

What is BNR's revenue and growth?

Burning Rock Biotech Ltd reported revenue of N/A.

Does BNR pay dividends?

Burning Rock Biotech Ltd does not currently pay dividends.

Where can I find BNR SEC filings?

Official SEC filings for Burning Rock Biotech Ltd (CIK: 0001792267) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is BNR's EPS?

Burning Rock Biotech Ltd has a diluted EPS of $0.00.

How is the AI analysis conducted?

Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 21, 2026 | Data as of: 2026-03-21 | Powered by Claude AI